Who Paid My Doc
Otis Brawley
Hematology & Oncology Atlanta, GA Medical Doctor
NPI 1912915109 CMS profile 389297
Winship Cancer Institute, 1365 Clifton Rd., Ne Ste C4014, Atlanta, GA 30322
General payments
$88,813
Research payments
$7,065
Ownership & investment interest
$0
Through program year 2025, Otis Brawley of Atlanta, GA is reported in the CMS Open Payments database as having received $88,813 across 62 general payments and $7,065 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 92nd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $22,828 | 20 | |
| 2024 | General | $23,831 | 13 | |
| 2023 | General | $11,320 | 7 | |
| 2022 | General | $12,051 | 6 | |
| 2021 | General | $9,240 | 5 | |
| 2021 | Research | $7,065 | 2 | |
| 2020 | General | $5,405 | 5 | |
| 2019 | General | $4,140 | 6 |
Beside peers
- Otis Brawley
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Otis Brawley were reported at $22,828. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Otis Brawley | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,140 | $529 | $121–$2,516 | $163 |
| 2020 | $5,405 | $339 | $82–$2,213 | $114 |
| 2021 | $9,240 | $263 | $49–$1,965 | $132 |
| 2022 | $12,051 | $416 | $103–$2,395 | $149 |
| 2023 | $11,320 | $542 | $125–$2,646 | $160 |
| 2024 | $23,831 | $692 | $141–$3,008 | $164 |
| 2025 | $22,828 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
64
Drug cost
$403,042
Branded share of claims
40.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | Brand | 15 | $171,280 | |
| Nubeqa Darolutamide | Brand | 11 | $148,640 | |
| Abiraterone Acetate | Generic | 27 | $82,810 | |
| Bicalutamide | Generic | 11 | $311 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$30,643
Medicare patients
39
Services billed
2,155
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 75% | |
| Arthritis | 51% | |
| Ischemic heart disease | 49% | |
| Diabetes | 31% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 17 | 148 | $20,433 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
64 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Georgia
Priya Rudolph
Hematology & Oncology · Athens, GA
Aron Kefela
Hematology & Oncology · Hiram, GA
Chandar Bhimani
Hematology & Oncology · Conyers, GA
Ticiana Leal
Hematology & Oncology · Atlanta, GA
Steven McCune
Hematology & Oncology · Marietta, GA
Jorge Leguizamo
Hematology & Oncology · Lawrenceville, GA
Related records
Hematology & Oncology in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.